News

Acadia's Alzheimer's psychosis drug remlifanserin posts Phase 3-enabling Phase 2 results

What's the deal? On 24 September ️2026 ACADIA Pharmaceuticals announced Phase 3-enabling topline results from the Phase 2 RADIANT study of remlifanserin for the treatment of Alzheimer's disease psychosis (ADP. ADP is the hallucinations and delusions that can accompany Alzheimer's disease, and there are currently no approved therapies for it. Remlifanserin is an oral, once-daily investigational candidate targeting serotonin receptors implicated in psychosis.

The results: The 60 mg dose achieved a change from baseline of -12.6 on the primary endpoint, the Scale for the Assessment of Positive Symptoms — Hallucinations and Delusions subscales(SAPS-H+D, versus -10.4 for placebo at week 6, a standardized effect size of0.26 with p=0.0603. That narrowly missed conventional statistical significance. On the key secondary endpoint, Clinical Global Impression — Severity for ADP,the 60 mg dose showed -1.3 versus -0.9 for placebo, effect size0.37 and nominal p=0.0077. The 30 mg dose showed minimal improvement across endpoints. The differences between60 mg and placebo widened through the six-week treatment period, and the company described the efficacy trend as meaningful and consistent across endpoints.

Why it matters: The data support continuing the Phase 3 programme; ACADIA plans to keep enrolling its two ongoing Phase 3 studies while amending them to remove the 30 mg dose arm. Safety was favorable across both doses,with rates of adverse events,serious adverse events,and discontinuations similar to placebo,no signal of QT prolongation(a heart-rhythm safety concern,and no apparent negative impact on motor symptoms or cognition. Detailed results will be presented at the Clinical Trials on Alzheimer's Disease(CTAD) conference this November.

Read more: Business Wire (company release, via Seeking Alpha), 24 September ️2026

More top stories